
EU approves Idelvion for haemophilia B treatment
pharmafile | May 13, 2016 | News story | Medical Communications, Research and Development | CSL, EU, Idelvion, approval, haemophilia B
The European Commission has approved Idelvion, coagulation Factor IX (recombinant) for the treatment and prophylaxis of bleeding in patients with haemophilia B.
Approved in children and adults, the indicated treatment regimen includes routine prophylaxis to prevent or reduce the frequency of bleeding episodes; on demand control; and the perioperative management of bleeding around the time of surgery.
Also recently approved in the US and Canada, Idelvion has demonstrated efficacy in maintaining Factor IX activity levels above 5% in most patients over 14 days.
Dr Andrew Cuthbertson, chief scientific officer at CSL, says: “Idelvion provides excellent bleeding control by maintaining factor IX activity levels above 5% over a prolonged period of time… We look forward to bringing Idelvion to the European market and are particularly excited about the positive impact this long-acting therapy can have on the lives of patients with haemophilia B.”
Sean Murray
Related Content

AstraZeneca’s Trixeo approved in EU for asthma in patients aged 12 and over
AstraZeneca’s Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate) has been approved by the European Commission as a …

AstraZeneca’s Trixeo approved in EU for asthma
AstraZeneca’s Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate) has been approved in the European Union as a …

Sharp invests $100m in US and EU manufacturing and packaging facilities
Sharp Services, a pharmaceutical packaging and sterile manufacturing specialist, has announced investments totalling $100m across …






